Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Salvarani

Showing results (581-590 of 625) with videos related to

Pageof 63
Sort By:
Arthritis and Rheumatism|March 6, 2012
2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiativeBhaskar Dasgupta, Marco A Cimmino, Hilal Maradit Kremers, et al.
Journal of Autoimmunity|October 2, 2021
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohortMariele Gatto, Francesca Saccon, Laura Andreoli, et al.
Frontiers in Pharmacology|November 9, 2016
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational StudyAntonio Vitale, Antonella Insalaco, Paolo Sfriso, et al.
Journal of Autoimmunity|January 14, 2020
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictorsLuca Quartuccio, Milena Bond, Miriam Isola, et al.
Annals of the Rheumatic Diseases|July 3, 2026
Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroupsGonzalo Borrego-Yaniz, Vera Fuentes-Moreno, Lourdes Ortiz-Fernández, et al.
Clinical Rheumatology|May 18, 2018
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational studyJurgen Sota, Antonio Vitale, Antonella Insalaco, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 4, 2021
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational StudyAlessandra Bettiol, Maria Letizia Urban, Lorenzo Dagna, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2020
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life SettingMariele Gatto, Francesca Saccon, Margherita Zen, et al.
Journal of Personalized Medicine|April 28, 2023
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS)Margherita Zen, Mariele Gatto, Roberto Depascale, et al.
Rheumatology (Oxford, England)|August 7, 2021
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patientsArsène Mekinian, Lucie Biard, Lorenzo Dagna, et al.
Pageof 63

Showing results (581-590 of 625) with videos related to

Sort By:
Pageof 63
Arthritis and Rheumatism|March 6, 2012
2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiativeBhaskar Dasgupta, Marco A Cimmino, Hilal Maradit Kremers, et al.
Journal of Autoimmunity|October 2, 2021
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohortMariele Gatto, Francesca Saccon, Laura Andreoli, et al.
Frontiers in Pharmacology|November 9, 2016
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational StudyAntonio Vitale, Antonella Insalaco, Paolo Sfriso, et al.
Journal of Autoimmunity|January 14, 2020
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictorsLuca Quartuccio, Milena Bond, Miriam Isola, et al.
Annals of the Rheumatic Diseases|July 3, 2026
Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroupsGonzalo Borrego-Yaniz, Vera Fuentes-Moreno, Lourdes Ortiz-Fernández, et al.
Clinical Rheumatology|May 18, 2018
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational studyJurgen Sota, Antonio Vitale, Antonella Insalaco, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 4, 2021
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational StudyAlessandra Bettiol, Maria Letizia Urban, Lorenzo Dagna, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2020
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life SettingMariele Gatto, Francesca Saccon, Margherita Zen, et al.
Journal of Personalized Medicine|April 28, 2023
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS)Margherita Zen, Mariele Gatto, Roberto Depascale, et al.
Rheumatology (Oxford, England)|August 7, 2021
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patientsArsène Mekinian, Lucie Biard, Lorenzo Dagna, et al.
Pageof 63